Debug Stats | ### Total Build Time: 25 ms 31.006 KB CONCEPT_NAME gt=11 ms Completed: 11 ms rowSize= 336 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 395 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=5 ms Completed: 5 ms rowSize= 14.285 KBCONCEPT_GENES gt=6 ms Completed: 6 ms rowSize= 14.783 KBCONCEPT_XREFS gt=3 ms Completed: 3 ms rowSize= 1.153 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (9)
Species: human : 9 | |
Human | NDRG2 | 57447 | NDRG family member 2 | Loss of NDRG2 expression was also seen in a subset of lower-grade meningiomas, including atypical meningiomas (WHO grade II) with clinically aggressive behavior. | Human | CADM1 | 23705 | cell adhesion molecule 1 | Moreover, TSLC1 loss was associated with decreased patient survival, within the overall group, and in the atypical meningiomas. | Human | WRN | 7486 | Werner syndrome, RecQ helicase-like | Atypical meningioma in Werner syndrome: a case report. | Human | TP53 | 7157 | tumor protein p53 | Atypical meningioma showed TP53 mutations and a 22q loss of heterozygosity (LOH), while glioblastoma showed epidermal growth factor receptor (EGFR) amplification and TP53 mutations | Human | TERC | 7012 | telomerase RNA component | In order to characterize factors that may influence this behavior, we chose to compare MIB-1 labeling index (LI) and telomerase RNA localization (hTR) in papillary meningiomas, meningiomas, and atypical meningiomas. hTR further delineated papillary (moderate to high) from atypical meningiomas (low). Atypical meningiomas showed 1 + hTR. | Human | CD46 | 4179 | CD46 molecule, complement regulatory protein | The benign and atypical meningiomas, and the astrocytomas showed high expression of SP-40,40, low expression of CD59, and barely detectable expression of CD46, CD55 and S-protein. | Human | CENPF | 1063 | centromere protein F, 350/400kDa | We conclude that mitosin immunohistochemical expression, although failing to discriminate between benign and atypical meningiomas, may be of use as a novel cell proliferation marker and as a predictor of tumor recurrence. The expression of mitosin, a novel proliferation-associated molecule was evaluated immunohistochemically in a consecutive series of 47 patients with primary intracranial benign and atypical meningiomas. | Human | CDKN2C | 1031 | cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) | We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppressor genes CDKN2A (p16(INKa)/MTS1), p14(ARF), CDKN2B (p15(INK4b)/MTS2) (all located at 9p21) and CDKN2C (1p32). One atypical meningioma with loss of heterozygosity on 1p carried a somatic CDKN2C mutation (c.202C>T: R68X). | Human | CDKN2B | 1030 | cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppressor genes CDKN2A (p16(INKa)/MTS1), p14(ARF), CDKN2B (p15(INK4b)/MTS2) (all located at 9p21) and CDKN2C (1p32). Six anaplastic meningiomas (46%) and one atypical meningioma (3%) showed homozygous deletions of the CDKN2A, p14(ARF), and CDKN2B genes. One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. |
|